LTT Biopharma Interstitial Pneumonia Drug Obtains MHLW Orphan Status
This article was originally published in PharmAsia News
Executive Summary
The First Committee on New Drugs at the Ministry of Health, Labor and Welfare June 4 granted orphan drug status to LTT Biopharma's midismase (recombinant) for interstitial pneumonia. Midismase is a lecithinized superoxide dismutase (PC-SOD) that is in Phase II clinical trials in Japan. Tokyo-based LTT specializes in developing new drug delivery systems, and the orphan status will accelerate the regulatory approval process and help obtain financial assistance. (Click here for more - Japanese language)"LTT Biopharma Shares Jump Due To Obtaining Orphan Drug Status For New Drug" - Search China News (6/7/2010)